Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal...

Full description

Saved in:
Bibliographic Details
Published inExpert review of vaccines Vol. 23; no. 1; pp. 546 - 560
Main Authors Nakamura, Shigeki, Mikami, Masashi, Hayamizu, Tomoyuki, Yonemoto, Naohiro, Moyon, Camille, Gouldson, Mark, Crossan, Catriona, Vietri, Jeffrey, Kamei, Kazumasa
Format Journal Article
LanguageEnglish
Published England Taylor & Francis Group 31.12.2024
Subjects
Cost-effectiveness
invasive pneumococcal disease
Japan
PCV20
pneumococcal disease
vaccination
invasive pneumococcal disease
Cost-effectiveness
Japan
PCV20
pneumococcal disease
vaccination
Online AccessGet full text

Cover

Abstract The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60-64 years in Japan. Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective. In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY). PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.
AbstractList The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60-64 years in Japan. Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective. In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY). PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.
Background The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60–64 years in Japan.Research design and methods Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective.Results In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY).Conclusions PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60–64 years in Japan.
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60-64 years in Japan.BACKGROUNDThe 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60-64 years in Japan.Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective.RESEARCH DESIGN AND METHODSUsing a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective.In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY).RESULTSIn comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY).PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.CONCLUSIONSPCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.
Author Kamei, Kazumasa
Nakamura, Shigeki
Moyon, Camille
Gouldson, Mark
Crossan, Catriona
Mikami, Masashi
Yonemoto, Naohiro
Hayamizu, Tomoyuki
Vietri, Jeffrey
Author_xml – sequence: 1
  givenname: Shigeki
  orcidid: 0000-0001-5272-8886
  surname: Nakamura
  fullname: Nakamura, Shigeki
– sequence: 2
  givenname: Masashi
  orcidid: 0000-0001-7731-847X
  surname: Mikami
  fullname: Mikami, Masashi
– sequence: 3
  givenname: Tomoyuki
  orcidid: 0009-0002-2989-4303
  surname: Hayamizu
  fullname: Hayamizu, Tomoyuki
– sequence: 4
  givenname: Naohiro
  orcidid: 0000-0003-3637-2095
  surname: Yonemoto
  fullname: Yonemoto, Naohiro
– sequence: 5
  givenname: Camille
  surname: Moyon
  fullname: Moyon, Camille
– sequence: 6
  givenname: Mark
  orcidid: 0009-0006-7259-0881
  surname: Gouldson
  fullname: Gouldson, Mark
– sequence: 7
  givenname: Catriona
  surname: Crossan
  fullname: Crossan, Catriona
– sequence: 8
  givenname: Jeffrey
  orcidid: 0000-0002-5610-3098
  surname: Vietri
  fullname: Vietri, Jeffrey
– sequence: 9
  givenname: Kazumasa
  orcidid: 0000-0001-7220-5142
  surname: Kamei
  fullname: Kamei, Kazumasa
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38703180$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1v1DAQhi1URD_gJ4By5JIy_koccUIrPooqcYGzNXHGlVdZe4mdSv339bLbSnDhMjMaPe870ryX7CymSIy95XDNwcAHrvoOtFHXAkQtUtfWvWAXvFeqNXLQZ3WuTHuAztllzlsAqQbdv2Ln0vQguYEL5jcpl5a8J1fCPUXKucGI80MOuUm-wWmdS7OPtO6SS87h3LgUt-sdFmru0blQJY1Py9_MFDJhpibE5jvuMb5mLz3Omd6c-hX79eXzz8239vbH15vNp9vWKSFKK7wYRQ-j7Oskicw49JyPUmo9GBjVJBDIkUNRuUkSyq4z0nmjFU1m4PKK3Rx9p4Rbu1_CDpcHmzDYP4u03FlcSnAzWS3kME2mo0GCAiMGAjE6g06MvpO8r17vj177Jf1eKRe7C9nRPGOktGYrQcOghDZQ0XcndB13ND0ffvpzBfQRcEvKeSH_jHCwhzztU572kKc95Vl1H__RuVCwhBTLgmH-j_oRJRCkUw
CitedBy_id crossref_primary_10_1080_13696998_2024_2445429
Cites_doi 10.1016/j.vaccine.2013.10.024
10.1080/21645515.2019.1690332
10.1371/journal.pone.0177342
10.1371/journal.pone.0139140
10.1097/QAD.0000000000003126
10.1016/j.ijid.2021.12.365
10.1038/nri2494
10.1016/j.vaccine.2022.10.010
10.1016/j.vaccine.2021.07.004
10.1007/s11136-015-1108-2
10.7326/0003-4819-138-12-200306170-00007
10.1371/journal.pmed.1003326
10.1093/cid/ciaa595
10.1016/S1473-3099(17)30049-X
10.1056/NEJMoa1408544
10.1186/s41479-017-0042-1
10.1080/14760584.2023.2273892
10.1001/jama.2014.18229
10.1016/S0140-6736(97)07358-3
10.7326/M13-2826
10.1002/14651858.CD000422.pub3
10.1007/s11606-016-3651-0
10.1016/j.chpulm.2023.100007
10.1371/journal.pone.0184877
10.1017/S0950268816000856
10.1056/NEJMoa0903029
10.1016/j.vaccine.2023.07.016
10.1093/cid/ciaa1045
10.1016/j.eclinm.2018.12.007
10.1371/journal.pone.0122247
10.1136/bmjopen-2017-018553
10.1136/bmjresp-2020-000703
10.1016/j.vaccine.2024.01.004
10.1080/21645515.2021.1875760
10.1093/cid/ciab990
10.1038/s41598-022-06950-w
10.1080/14737167.2022.2134120
10.1080/14760584.2023.2262575
10.1016/j.trivac.2016.04.004
10.57598/R274CS
10.1016/j.vaccine.2019.12.029
10.1016/j.vaccine.2022.09.055
10.1186/s12962-023-00458-4
10.1056/NEJM198611203152104
10.1183/13993003.00325-2015
10.1080/13696998.2022.2152235
10.1056/NEJMoa035060
10.1186/2191-1991-2-4
10.1007/s10096-007-0327-z
10.1186/s12890-016-0199-z
10.1080/14760584.2021.1952869
10.1016/S0264-410X(02)00451-6
10.1016/j.amepre.2012.11.035
10.1016/j.ijid.2020.10.017
10.4161/hv.23268
10.1001/archinte.167.18.1938
10.1017/S0950268815001971
ContentType Journal Article
DBID AAYXX
CITATION
NPM
7X8
DOA
DOI 10.1080/14760584.2024.2350246
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1744-8395
EndPage 560
ExternalDocumentID oai_doaj_org_article_5239dd86e93040829e02bc8ac2bf6317
38703180
10_1080_14760584_2024_2350246
Genre Journal Article
GroupedDBID ---
0YH
29G
4.4
53G
5GY
AAYXX
ABEIZ
ABLKL
ABXYU
ACGFS
ADCVX
AECIN
AENEX
AEOZL
AESAV
AFRVT
AGDLA
AHMBA
AIJEM
AIYSM
AKBVH
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALQZU
BLEHA
CCCUG
CITATION
CS3
DU5
EBS
F5P
GROUPED_DOAJ
H13
HZ~
IAO
IHR
KYCEM
LJTGL
M4Z
MV1
O9-
P2P
SJN
TCNNB
TDBHL
TFL
TFW
TUROJ
NPM
7X8
ID FETCH-LOGICAL-c422t-2f2b270b372f23ee8b9711b3355980b4d2a0ececa22b2d3ea36683cf854ed8913
IEDL.DBID DOA
ISSN 1476-0584
1744-8395
IngestDate Wed Aug 27 00:54:57 EDT 2025
Fri Jul 11 02:10:27 EDT 2025
Mon Jul 21 06:07:18 EDT 2025
Thu Apr 24 23:10:10 EDT 2025
Thu Jul 10 08:16:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords invasive pneumococcal disease
Cost-effectiveness
Japan
PCV20
pneumococcal disease
vaccination
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c422t-2f2b270b372f23ee8b9711b3355980b4d2a0ececa22b2d3ea36683cf854ed8913
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-5272-8886
0009-0002-2989-4303
0000-0003-3637-2095
0000-0002-5610-3098
0009-0006-7259-0881
0000-0001-7220-5142
0000-0001-7731-847X
OpenAccessLink https://doaj.org/article/5239dd86e93040829e02bc8ac2bf6317
PMID 38703180
PQID 3050942580
PQPubID 23479
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_5239dd86e93040829e02bc8ac2bf6317
proquest_miscellaneous_3050942580
pubmed_primary_38703180
crossref_primary_10_1080_14760584_2024_2350246
crossref_citationtrail_10_1080_14760584_2024_2350246
PublicationCentury 2000
PublicationDate 2024-12-31
PublicationDateYYYYMMDD 2024-12-31
PublicationDate_xml – month: 12
  year: 2024
  text: 2024-12-31
  day: 31
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Expert review of vaccines
PublicationTitleAlternate Expert Rev Vaccines
PublicationYear 2024
Publisher Taylor & Francis Group
Publisher_xml – name: Taylor & Francis Group
References e_1_3_6_53_1
e_1_3_6_76_1
e_1_3_6_32_1
e_1_3_6_55_1
e_1_3_6_74_1
e_1_3_6_11_1
e_1_3_6_72_1
e_1_3_6_51_1
e_1_3_6_70_1
e_1_3_6_15_1
e_1_3_6_38_1
(e_1_3_6_18_1) 2023
e_1_3_6_13_1
e_1_3_6_19_1
e_1_3_6_34_1
e_1_3_6_57_1
e_1_3_6_17_1
e_1_3_6_36_1
e_1_3_6_59_1
e_1_3_6_78_1
e_1_3_6_42_1
e_1_3_6_65_1
e_1_3_6_88_1
e_1_3_6_21_1
e_1_3_6_44_1
e_1_3_6_63_1
e_1_3_6_86_1
e_1_3_6_61_1
e_1_3_6_84_1
e_1_3_6_40_1
e_1_3_6_82_1
e_1_3_6_6_1
e_1_3_6_80_1
e_1_3_6_4_1
(e_1_3_6_30_1) 2007
e_1_3_6_8_1
e_1_3_6_27_1
e_1_3_6_29_1
e_1_3_6_23_1
e_1_3_6_46_1
e_1_3_6_69_1
e_1_3_6_25_1
e_1_3_6_48_1
e_1_3_6_67_1
e_1_3_6_31_1
e_1_3_6_52_1
e_1_3_6_77_1
e_1_3_6_33_1
e_1_3_6_54_1
e_1_3_6_75_1
e_1_3_6_10_1
e_1_3_6_73_1
e_1_3_6_50_1
e_1_3_6_71_1
Leidner AJ (e_1_3_6_14_1) 2021
e_1_3_6_39_1
e_1_3_6_12_1
e_1_3_6_35_1
e_1_3_6_56_1
e_1_3_6_16_1
e_1_3_6_37_1
e_1_3_6_58_1
e_1_3_6_79_1
e_1_3_6_20_1
e_1_3_6_41_1
e_1_3_6_66_1
e_1_3_6_87_1
e_1_3_6_22_1
e_1_3_6_43_1
e_1_3_6_64_1
e_1_3_6_85_1
e_1_3_6_62_1
e_1_3_6_83_1
e_1_3_6_81_1
e_1_3_6_60_1
e_1_3_6_5_1
e_1_3_6_3_1
e_1_3_6_9_1
e_1_3_6_7_1
e_1_3_6_28_1
e_1_3_6_49_1
e_1_3_6_24_1
e_1_3_6_45_1
e_1_3_6_26_1
e_1_3_6_47_1
e_1_3_6_68_1
e_1_3_6_89_1
References_xml – ident: e_1_3_6_45_1
  doi: 10.1016/j.vaccine.2013.10.024
– ident: e_1_3_6_10_1
  doi: 10.1080/21645515.2019.1690332
– ident: e_1_3_6_48_1
  doi: 10.1371/journal.pone.0177342
– ident: e_1_3_6_49_1
  doi: 10.1371/journal.pone.0139140
– ident: e_1_3_6_84_1
  doi: 10.1097/QAD.0000000000003126
– ident: e_1_3_6_27_1
– ident: e_1_3_6_35_1
– ident: e_1_3_6_75_1
  doi: 10.1016/j.ijid.2021.12.365
– ident: e_1_3_6_13_1
  doi: 10.1038/nri2494
– ident: e_1_3_6_23_1
  doi: 10.1016/j.vaccine.2022.10.010
– ident: e_1_3_6_8_1
– ident: e_1_3_6_22_1
  doi: 10.1016/j.vaccine.2021.07.004
– ident: e_1_3_6_26_1
– ident: e_1_3_6_68_1
  doi: 10.1007/s11136-015-1108-2
– ident: e_1_3_6_12_1
– ident: e_1_3_6_34_1
– ident: e_1_3_6_9_1
– ident: e_1_3_6_73_1
– ident: e_1_3_6_3_1
– ident: e_1_3_6_56_1
  doi: 10.7326/0003-4819-138-12-200306170-00007
– ident: e_1_3_6_52_1
  doi: 10.1371/journal.pmed.1003326
– ident: e_1_3_6_70_1
  doi: 10.1093/cid/ciaa595
– ident: e_1_3_6_17_1
  doi: 10.1016/S1473-3099(17)30049-X
– ident: e_1_3_6_39_1
  doi: 10.1056/NEJMoa1408544
– ident: e_1_3_6_66_1
  doi: 10.1186/s41479-017-0042-1
– ident: e_1_3_6_62_1
  doi: 10.1080/14760584.2023.2273892
– ident: e_1_3_6_87_1
  doi: 10.1001/jama.2014.18229
– ident: e_1_3_6_6_1
– ident: e_1_3_6_54_1
  doi: 10.1016/S0140-6736(97)07358-3
– ident: e_1_3_6_31_1
  doi: 10.7326/M13-2826
– ident: e_1_3_6_53_1
  doi: 10.1002/14651858.CD000422.pub3
– ident: e_1_3_6_58_1
  doi: 10.1007/s11606-016-3651-0
– ident: e_1_3_6_78_1
– ident: e_1_3_6_5_1
  doi: 10.1016/j.chpulm.2023.100007
– ident: e_1_3_6_85_1
  doi: 10.1371/journal.pone.0184877
– volume-title: ACIP Meeting: Centers for Disease Control and Prevention
  year: 2021
  ident: e_1_3_6_14_1
– ident: e_1_3_6_88_1
  doi: 10.1017/S0950268816000856
– ident: e_1_3_6_41_1
  doi: 10.1056/NEJMoa0903029
– ident: e_1_3_6_61_1
  doi: 10.1016/j.vaccine.2023.07.016
– ident: e_1_3_6_21_1
  doi: 10.1093/cid/ciaa1045
– ident: e_1_3_6_43_1
  doi: 10.1016/j.eclinm.2018.12.007
– ident: e_1_3_6_79_1
  doi: 10.1371/journal.pone.0122247
– ident: e_1_3_6_29_1
  doi: 10.1136/bmjopen-2017-018553
– ident: e_1_3_6_77_1
– ident: e_1_3_6_86_1
  doi: 10.1136/bmjresp-2020-000703
– ident: e_1_3_6_20_1
  doi: 10.1016/j.vaccine.2024.01.004
– ident: e_1_3_6_32_1
– ident: e_1_3_6_80_1
– ident: e_1_3_6_72_1
– ident: e_1_3_6_37_1
  doi: 10.1080/21645515.2021.1875760
– ident: e_1_3_6_19_1
  doi: 10.1093/cid/ciab990
– ident: e_1_3_6_64_1
  doi: 10.1038/s41598-022-06950-w
– ident: e_1_3_6_24_1
  doi: 10.1080/14737167.2022.2134120
– ident: e_1_3_6_60_1
  doi: 10.1080/14760584.2023.2262575
– ident: e_1_3_6_16_1
  doi: 10.1016/j.trivac.2016.04.004
– volume-title: Application for manufacturing and sales approval for precipitated 20-valent pneumococcal conjugate vaccine
  year: 2023
  ident: e_1_3_6_18_1
– ident: e_1_3_6_81_1
– ident: e_1_3_6_15_1
– ident: e_1_3_6_69_1
  doi: 10.57598/R274CS
– ident: e_1_3_6_76_1
– ident: e_1_3_6_59_1
  doi: 10.1016/j.vaccine.2019.12.029
– ident: e_1_3_6_38_1
  doi: 10.1016/j.vaccine.2022.09.055
– ident: e_1_3_6_82_1
  doi: 10.1186/s12962-023-00458-4
– ident: e_1_3_6_55_1
  doi: 10.1056/NEJM198611203152104
– ident: e_1_3_6_11_1
– ident: e_1_3_6_4_1
– ident: e_1_3_6_40_1
  doi: 10.1183/13993003.00325-2015
– ident: e_1_3_6_28_1
– ident: e_1_3_6_83_1
  doi: 10.1080/13696998.2022.2152235
– ident: e_1_3_6_71_1
– ident: e_1_3_6_42_1
  doi: 10.1056/NEJMoa035060
– ident: e_1_3_6_7_1
– ident: e_1_3_6_33_1
– ident: e_1_3_6_51_1
  doi: 10.1186/2191-1991-2-4
– ident: e_1_3_6_46_1
  doi: 10.1007/s10096-007-0327-z
– ident: e_1_3_6_74_1
– ident: e_1_3_6_67_1
  doi: 10.1186/s12890-016-0199-z
– ident: e_1_3_6_25_1
  doi: 10.1080/14760584.2021.1952869
– ident: e_1_3_6_47_1
  doi: 10.1016/S0264-410X(02)00451-6
– ident: e_1_3_6_57_1
  doi: 10.1016/j.amepre.2012.11.035
– ident: e_1_3_6_63_1
– ident: e_1_3_6_65_1
  doi: 10.1016/j.ijid.2020.10.017
– start-page: 2
  year: 2007
  ident: e_1_3_6_30_1
  article-title: The JRS guidelines for the management of community acquired pneumonia in adults
  publication-title: Nihon Kokyuki Gakkai Zasshi
– ident: e_1_3_6_36_1
– ident: e_1_3_6_44_1
  doi: 10.4161/hv.23268
– ident: e_1_3_6_50_1
  doi: 10.1001/archinte.167.18.1938
– ident: e_1_3_6_89_1
  doi: 10.1017/S0950268815001971
SSID ssj0034957
Score 2.4251518
Snippet The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased...
Background The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with...
SourceID doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
StartPage 546
SubjectTerms Cost-effectiveness
invasive pneumococcal disease
Japan
PCV20
pneumococcal disease
vaccination
Title Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
URI https://www.ncbi.nlm.nih.gov/pubmed/38703180
https://www.proquest.com/docview/3050942580
https://doaj.org/article/5239dd86e93040829e02bc8ac2bf6317
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NS-UwEA8iCF7Er12frhLBazVN0r70uCuKCHpS8FbyMQFltxXfe4L_vTNN-tDD4sVLW4aEpjPT-cjHbxg7CSHYUCpdNBB1oRvli8aCKEIUNZRlxCyDpgZubuure339UD18KPVFe8ISPHBi3BkmSk0IpoYGE286CApCOm-sly7W6PzI-qLPG5OpZIMVhv1DWRU9xXwZfex4dseIM6IRCXNDiRdV4a3-5JUG8P7_R5yD57ncZBs5ZOS_01C32Ap022wtFZF822HxvJ_Ni7QvI5subjPUCO8jHxA2-HMHi389Wj-UCccc-GlB82f81XpaWZ9xjF0_t8krN_yx49foULtddn95cXd-VeTqCYXXUs4LGaWTU-HUFJ8UgHHNtCydUgTJLpwO0grw4K3EdkGBVXVtlI-m0hBo8fIHW-36DvYYrxQ2qXykg7wYwFiLUYaJJjqkgxHVhOmRe63P0OJU4eJvW2YE0pHpLTG9zUyfsNNlt-eErfFVhz8kmmVjgsYeCKgwbVaY9iuFmbDjUbAt_kq0PmI76BezVhEWDtowIybsZ5L48lXKENC_EfvfMYQDtk6flfAif7HV-csCDjG2mbujQY3fATQi73Q
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cost-effectiveness+analysis+of+adult+pneumococcal+conjugate+vaccines+for+pneumococcal+disease+in+Japan&rft.jtitle=Expert+review+of+vaccines&rft.au=Shigeki+Nakamura&rft.au=Masashi+Mikami&rft.au=Tomoyuki+Hayamizu&rft.au=Naohiro+Yonemoto&rft.date=2024-12-31&rft.pub=Taylor+%26+Francis+Group&rft.issn=1476-0584&rft.eissn=1744-8395&rft.volume=23&rft.issue=1&rft.spage=546&rft.epage=560&rft_id=info:doi/10.1080%2F14760584.2024.2350246&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5239dd86e93040829e02bc8ac2bf6317
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-0584&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-0584&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-0584&client=summon